Profil
Morgan Sheng is a Professor at the Massachusetts Institute of Technology.
He was previously an Independent Director at Prevail Therapeutics, Inc. from 2019 to 2021 and a Vice President-Neuroscience at Genentech, Inc. He holds a doctorate degree from Harvard University and the University of London, and an undergraduate degree from the University of Oxford.
Aktiva positioner av Morgan Sheng
| Företag | Position | Start |
|---|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Företagsledare/Principal | - |
Tidigare kända positioner av Morgan Sheng
| Företag | Position | Slut |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Direktör/Styrelseledamot | 2021-01-22 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Företagsledare/Principal | - |
Morgan Shengs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prevail Therapeutics, Inc.
Prevail Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutics for neurodegenerative diseases | Health Technology |
















